more

Omnicell (OMCL)

(Delayed Data from NSDQ)

$50.14 USD

-2.32 (-4.42%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $50.16 +0.02 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

Top 18% (45 out of 250)

Industry: Medical Info Systems

View All Zacks #1 Ranked Stocks

Zacks News

Omnicell (OMCL) Misses Q4 Earnings Estimates

by Zacks Equity Research Published on February 06,2020

Omnicell (OMCL) delivered earnings and revenue surprises of -1.28% and 2.20%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

OMCLNegative Net Change

Omnicell (OMCL) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research Published on January 30,2020

Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OMCLNegative Net Change

Hill-Rom (HRC) Gains Ground on Global Expansion, New Menu

by Zacks Equity Research Published on January 21,2020

Hill-Rom (HRC) is optimistic about its latest buyouts of Breathe Technologies and Voalte, mirroring its outstanding capital management strategy in turn.

medical

Here's Why You Should Retain Edwards Lifesciences Stock Now

by Zacks Equity Research Published on January 21,2020

Investors can hold on to Edwards Lifesciences (EW) in their portfolio for now, thanks to solid prospects.

medical

Hologic (HOLX) Hits a 52-Week High: What's Driving the Stock?

by Zacks Equity Research Published on January 20,2020

Hologic (HOLX) gains from several positive developments.

medical

Integra Announces Preliminary Q4 Results, Share Buyback Plan

by Zacks Equity Research Published on January 16,2020

Integra (IART) projects fourth-quarter 2019 revenues at or near the low end of its previously-announced guidance.

medical

Here's Why You Should Add Bruker (BRKR) to Your Portfolio Now

by Zacks Equity Research Published on January 15,2020

Investor confidence in Bruker (BRKR) is at a high, thanks to solid prospects.

medical

5 Promising Growth Stocks in MedTech to Invest in 2020

by Trina Mukherjee Published on January 14,2020

We have zeroed in on five impressive growth stocks in MedTech on the back of the industry's lucrative prospects.

medical

Invest in These 5 Low Leverage Stocks Before Q4 Earnings

by Zacks Equity Research Published on January 13,2020

Companies displaying high earnings growth along with high leverage ratios should be avoided while making investment decisions. So, investors should select companies with low leverage.

Varian (VAR) Hits a 52-Week High: What's Driving the Stock?

by Zacks Equity Research Published on January 09,2020

Varian (VAR) gains from several positive developments.

medical

Amedisys Gains on Favorable Demography, New Hospice Buyouts

by Zacks Equity Research Published on January 07,2020

Amedisys (AMED) is steadily benefiting from its recent takeovers of hospice care providers, namely RoseRock Healthcare and Compassionate Care Hospice.

medical

Exact Sciences Rides on Cologuard, Eyes Merger Synergies

by Zacks Equity Research Published on January 07,2020

Exact Sciences (EXAS) continues to make a notable progress with its Cologuard business.

medical

Myriad Genetics' GUIDED Clinical Trial Outcome Encouraging

by Zacks Equity Research Published on January 07,2020

The result of this clinical trial is a major stride forward in Myriad Genetics' (MYGN) commitment toward strengthening its portfolio of depressive disorder treatments.

medical

Here's Why You Should Add STERIS (STE) to Portfolio Now

by Zacks Equity Research Published on January 07,2020

Investor confidence is high on STERIS (STE) stock for now, thanks to its solid prospects.

medical

LabCorp (LH) Grows on Solid Diagnostics Arm Despite PAMA Headwinds

by Urmimala Biswas Published on January 06,2020

LabCorp's (LH) Diagnostics business flourishes organically in terms of both revenues and volumes despite additional price reductions due to Protecting Access to Medicare Act (PAMA).

medical

Here's Why You Should Hold on to Phibro (PAHC) Stock Now

by Zacks Equity Research Published on January 06,2020

Investors can retain Phibro (PAHC) stock for now, thanks to its solid prospects.

medical

Illumina Stock Slips on Pacific Biosciences Deal Termination

by Zacks Equity Research Published on January 03,2020

Per Illumina (ILMN), the lengthy route to achieve regulatory nods for the transaction induces uncertainty about the ultimate outcome of the integration.